Coagulation in Cancer informs professionals working in the field of cancer about the pathophysiologic mechanisms of cancer-related thrombosis and bleeding. It provides assistance in recognizing the various bleeding and clotting disorders associated with cancer and includes current recommendations for the management of hemorrhage, and prevention and treatment of thrombosis in the patient with malignancy. This volume is a valuable addition to the literature on cancer and coagulation.

In this book, leaders in the field explore our current understanding of thrombosis and hemostasis in cancer and address key questions on the subject. Among the topics discussed are the mechanisms that cancers use to activate the coagulation system, and those by means of which an activated coagulation system can lead to more aggressive cancer growth. Clinical chapters examine the role of thrombosis prophylaxis and treatment, central line-associated thrombosis, and cancer-associated hemorrhage. Subsequent chapters deal with the management of chemotherapy-induced thrombocytopenia, anticoagulation in the presence of brain metastases, and other unique challenges in the interaction of thrombosis and hemostasis in cancer. It has been 150 years since Armand Trousseau first described the well-known association between cancer and an increased risk of thrombosis, which may be considered the first paraneoplastic syndrome ever identified. More recently, numerous studies have indicated that activation of the coagulation system by cancer not only increases the likelihood of thrombosis, but is also associated with a more aggressive cancer phenotype. By familiarizing readers with the latest developments in this complex and challenging field, the book offers a valuable resource for scientists and clinicians alike.

Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides

This book proposes the importance of new systems of drug design and delivery based on cancer pathophysiology in addition to cancer molecular and cellular biology. The current studies based on molecular and cellular biology while ignoring pathophysiology and pharmacology may be leading the development of antitumor drugs in the wrong direction and wasting a lot of money. Although there have been numerous reports of genetic and phenotypic changes in tumors, a large body of pathological and clinical evidence supports the conclusion that there are no pivotal changes in tumor cells that distinguish them consistently and reliably from normal dividing cells. Unlike using antibiotics against bacterial infection, therefore, anticancer agents (ACAs) need to be delivered selectively to tumor tissues and should be kept there long enough to reproduce the concentrations they reach in the Petri dish, which is a closed space where the cytocidal effects of any anticancer agents (ACAs) including molecular targeting agents are very strong. In the body, however, administered ACAs are cleared with the passage of time. Furthermore, most human cancers possess abundant stroma that hinders the penetration of drugs into the tumor microenvironment. Therefore, to overcome these difficulties, novel drug delivery systems have been designed, such as nanoparticles and ACA conjugated antibodies to stromal components and to cancer cell surface antigens. These advances are described in this book after the first section, which describes core features of the pathophysiology of the cancer microenvironment, on which these new developments are based.

This text provides comprehensive and timely coverage of the current knowledge of cancer-associated thrombosis, its pathogenesis, clinical features, prevention, and therapy. It specifically addresses the relationship between hemostatic systems and cancer, thus providing a unique and much needed focus. All of the contributors are acknowledged specialists in their fields and have experience conducting large clinical trials in oncology and thrombosis. Their discussions cover all aspects of the topic, from long-term complications to cancer surgery. It will be of interest to general practitioners, internists, oncologists, hematologists, and all physicians involved in the management of cancer patients.

The key aim of the proposed chapter is to provide readers a brief description for the most important parts of the field of circulating tumor cells (CTCs): the core techniques, including negative and positive selection-based CTC isolation, and the differences between them. Most importantly, we will also review the clinical applications and important findings in clinical trials. The evidence-based review will not only help clinicians use CTCs to predict recurrence and foresee the disease-related outcomes but also to inspire the researchers in this field to conduct further investigations.

There have been many changes in the field of coagulation during the past decade. New concepts of epidemiology of risk factors for thrombosis now help clinicians predict who is more likely to form clots after surgery, or after being placed on oral contraceptives. New anticoagulants have the potential to redefine how patients with atrial fibrillation and venous thrombosis are managed. There are new forms of recombinant clotting factors which have changed our approach to hypofibrinogenemia and von Willebrand’s disease. Newer antiplatelet agents are available and their use in patients receiving cardiac stents has mushroomed. The management of thrombosis in the setting of pregnancy has changed over the past decade, as well as the way clinicians approach women with multiple miscarriages. An entire new class of compounds, the thrombopoietins, are available to treat individuals with immune thrombocytopenic purpura (ITP). The Coagulation Consult covers major topics of interest to hematologists who are asked to consult on individuals with coagulation related diseases, and encompasses the field’s most recent developments. This “case-directed” book describes state-of-the-art approaches to patients with bleeding and clotting disorders, as well as laboratory tests for coagulation. Chapters include different vignettes, focus on typical clinical consult questions, and lay out specific types of treatment. Practicing clinicians being confronted with coagulation consult students, residents, fellows and attending physicians will find this unique text an invaluable resource for some of the newer areas of coagulation science, therapy and pharmacology.

An essential resource for diagnosis and treatment of stroke patients outside the usual clinical categories.

Coagulation in Cancer informs professionals working in the field of cancer about the pathophysiologic mechanisms of cancer-related thrombosis and bleeding. It provides assistance in recognizing the various bleeding and clotting disorders associated with cancer and includes current recommendations for the management of hemorrhage, and prevention and treatment of thrombosis in the patient with malignancy. This volume is a valuable addition to the literature on cancer and coagulation.

A unique clinical focus makes Consultative Hemostasis and Thrombosis, 3rd Edition your go-to guide for quick, practical answers on managing the full range of bleeding and clotting disorders. Emphasizing real-world problems and solutions, Dr. Craig S. Kitchens, Dr. Barbara A. Konkle, and Dr. Craig M. Kessler provide all the clinical guidance you need to make optimal decisions on behalf of your patients and promote the best possible outcomes. Consult this title on your favorite e-reader with intuitive search tools and adjustable font sizes. Elsevier eBooks provide instant portable access to your entire library, no matter what device you're using or where you're located. Efficiently look up concise descriptions of each condition, its associated symptoms, laboratory findings, diagnosis, differential diagnosis, and treatment. Get the latest information on hot topics such as Disseminated Intravascular Coagulation, Thrombophilia, Clinical and Laboratory Assessment and Management, Thrombotic -Thrombocytopenic Purpura, and Heparin-Induced Thrombocytopenia. Apply today’s newest therapies, including those that are quickly becoming standard in this fast-changing field. Meet the needs of specific patient groups with a new chapter on Bleeding and the Management of Hemorrhagic Disorders in Pregnancy and an extensively updated chapter on Thrombosis and Cancer. Zero in on key information with a new user-friendly design, and all-new full-color format, abundant laboratory protocols, and at-a-glance tables and charts throughout.